| Although combination chemotherapy has had a significant impact on survival for malignancies, the majority of cancers are either initially resistant to chemotherapy or are initially chemosensitive but acquire resistance during treatment. Resistance to chemotherapy remains an obstacle to the successful treatment of human cancer and has been the subject of numerous investigations aimed at identifying the molecular mechanism s of resistance in cancer cells. An improved understanding of the mechanisms by which tumor cells develop resistance to chemotherapy may not only enhance the activity of cytotoxic therapy in advanced malignancies but may ultimately improve the impact of adjuvant therapy. One mechanism of multidrug resistance is thought to be due to the efflux of anticancer drugs caused by P-glycoprotein and multidrug resistance gene(MDRl) overexpression. Because MDR can easily be reversed in vitro, efforts have been undertaken to circumvent resistance in clinical trials. Although there are many agents that can modulate MDR in vitro and in vivo models including calcium channel blockers, gene therapy and immunology, there is still an obstacle on clinical application because of side-effects. In recent years, magnetic fields have been found to enhance the potency of anticancer drugs, with favorable modulation of chemotherapy, but the mechanism is not very clear. In this study, a multidrug resistant(MDR) human lung adenocarcinoma subline, A549/DDP, was used as a model to evaluate the ability of extremely-low frequency alternative magnetic fields(ELFMF) to modulate the potency of DDP and ADR in vitro and in vivo and to investigate the relative...
|
PDF Full Text Request